INTRODUCTION:

Contraception is a right, being an obligation of the State to guarantee access to effective, safe and quality contraceptive methods. A health technology assessment was carried out on transdermal contraceptive patches .

METHODS:

A multidisciplinary and independent team appointed by the Provincial Biotechnology Committee of Neuquén searched for epidemiological and regulatory information and scientific evidence on efficacy, safety and adherence. It was analyzed and systematized following the GRADE (Grading of Recommendations Assessment, Development and Evaluation) and CASPe (Critical Appraisal Skills Programme Español) methodology .

RESULTS:

The only patch authorized for commercialization in Argentina releases 33.9 μg/day of ethinylestradiol and 203 μg/day of norelgestromin. Its package insert in Argentina, the US and Europe highlights that the risk of venous thromboembolic disease is twice as high compared to the contraceptive pills provided by the State. This is consistent with results from high-quality cohort studies. Patches provide similar short-term contraceptive efficacy, but with high dropout rates at follow-up. The World Health Organization has not included them in its list of essential medicines. Patches are more expensive than other available methods .

DISCUSSION:

Based on the principles of beneficence, non-maleficence, precaution and proportionality, the incorporation of patches is not recommended.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )